In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/PerSeptive Biosystems: PE expands its "proteomics" technology portfolio by completing proposed $360 mil. PerSeptive buy, a definitive stock-swap deal for which was announced on Aug. 25 ("The Gray Sheet" Sept. 1, 1997, p. 6). The combination will create a fully integrated technology platform in the field of biomedical research and drug discovery, PE claims...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: